Clinical Trials Sponsored by Shanghai baiying pharmaceutical technology Co., Ltd.

Total 945 results

Lepu Medical Technology (Beijing) Co., Ltd.

Unknown

NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

Coronary Artery Disease

China
Lepu Medical Technology (Beijing) Co., Ltd.

Unknown

NeoVas Bioresorbable Coronary Scaffold First-in-Man Study

Coronary Artery Disease

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

Axial Spondyloarthritis

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Acute Gout
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

The MAD Study of SSGJ-613 in Healthy Subjects

Arthritis, Gouty

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Acute Gout

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Branch Retinal Vein Occlusion

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Sarcoma, Soft Tissue

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Receptor, ErbB-2
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Completed

Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Completed

Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis

Dermatitis, Atopic

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Active, not recruiting

A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma

Asthma

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

Solid Tumors

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)

Wet Age-related Macular Degeneration

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

Moderate to Severe Plaque Psoriasis

China
Shenzhen Yangli Pharmaceutical Technology Co., Ltd

Recruiting

Study of TFX06 in Women With Advanced Breast Cancer.

Metastatic Breast Cancer | ER+, HER2- Advanced Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Jiangsu vcare pharmaceutical technology co., LTD

Recruiting

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Active Ankylosing Spondylitis

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Recruiting

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Treatment Side Effects | Treatment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Malignant Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI

Contrast-induced Acute Kidney Injury

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
Shenzhen Yangli Pharmaceutical Technology Co., Ltd

Recruiting

A Study of TFX05-01 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

Pancreatic Cancer | Advanced Solid Tumor | Gastric Cancer (GC) | Gastroesophageal Junction (GEJ) Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Heyu (Suzhou) Pharmaceutical Technology Co., Ltd

Recruiting

Phase I Clinical Study of HY01 in Patients

Sudden Sensorineural Hearing Loss

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
Jiangsu vcare pharmaceutical technology co., LTD

Recruiting

The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors

Metastatic Solid Tumor | Locally Advanced Solid Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Jianersheng (Zhuhai) Pharmaceutical Technology...

Completed

Safety Study of GMDTC Injection in Healthy Participants

Cadmium Exposure

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

SARS-CoV-2 Infection

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China
Jiangsu vcare pharmaceutical technology co., LTD

Completed

Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

China
Jiangsu vcare pharmaceutical technology co., LTD

Completed

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

Inflammatory Bowel Diseases

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

China

Clinical Trials Sponsored by Shanghai baiying pharmaceutical technology Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations